Zydus Lifesciences Limited — PPTs, 20-05-2025: Investor Presentation

1. Financial Highlights:

Zydus Lifesciences posted revenues of Rs. 652.79 Cr, up 18% YoY led by growth in India branded formulations, US generics, consumer wellness, and international markets. EBITDA rose 30% YoY to Rs. 212.55 Cr with margins expanding 310 bps to 32.6%. Net profit excluding exceptional items increased 18% YoY to Rs. 139.05 Cr. R&D spend was Rs. 47.99 Cr (7.4% of sales). Net cash jumped sharply to Rs. 488.36 Cr from Rs. 85.61 Cr, and organic capex was Rs. 32.02 Cr. Gross margin improved to 74%, reflecting strong operational leverage.

2. Strategic Initiatives & Growth Drivers:

India branded formulations grew 11% YoY with chronic therapy now 43% of the portfolio. Consumer wellness showed double-digit expansion aided by the Naturell India acquisition, boosting snacks and nutrition presence. US formulations surged 24% YoY with 17 new launches, 27 ANDA filings, and 24 approvals in FY25, including specialty Sitagliptin brands. International business grew 11.8%, benefiting from targeted therapy expansion and global R&D pipeline. Innovation continues with Phase II/III trials for Saroglitazar Magnesium and advanced vaccine development supported by the Gates Foundation.

3. Business Developments:

Zydus entered MedTech through majority acquisition of France-based Amplitude Surgical, enhancing its orthopedic R&D capabilities. Exclusive US licensing secured for oncology product BEIZRAY (Docetaxel injection). Collaboration with Synthon BV underway for a novel oncology 505(B)(2) product targeting NDA filing in 2026.

4. Market Position & Competitive Advantage:

Zydus ranks as India’s 5th largest pharma and is among the top 3 US generics firms by prescriptions, with leadership in wellness segments. Its broad portfolio spans novel drugs, biosimilars, generics, and wellness products, supported by strong innovation and global manufacturing scale. Heavy R&D investments and specialty product focus aim to boost value-chain positioning.

5. Investor Implications:

Diverse business mix, expanding innovation pipeline, and MedTech expansion present visible positive growth potential. Strong cash flows and margin gains support continued reinvestment. Execution risks exist around clinical trials and acquisition integration, but robust demand and new product launches underpin a confident outlook for sustained outperformance.